Tirbanubulin for superficial basal cell carcinoma
Part of Cancer, Skin clinical trials.
This trial tests the safety and effectiveness of tirbanubulin gel to treat a type of skin cancer called superficial basal cell carcinoma (sBCC). It is for people who have not been treated for this cancer before and have a small spot (less than 1.5 cm) that is not on the face or scalp.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a newly diagnosed, untreated, superficial basal cell carcinoma (BCC) confirmed by biopsy
- The BCC must be on your body (not on your face, scalp, or genitals) and be 15 millimeters or smaller in the longest direction
- You cannot have had other treatments like cryotherapy, imiquimod, photodynamic therapy, or radiation on that same BCC spot in the last 6 months
- You must not have any known allergy to tirbanubulin or any ingredient in the gel
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of fractional laser and tirbanibulin ointment to treat basal or squamous cell skin cancer that hasn't been treated before. It may offer a less invasive option for people with these common skin cancers.
This study tests a cream called tirbanibulin (Klisyri) for adults with 4 to 12 actinic keratosis (AK) spots on their face. It aims to see how well the treatment works when applied to a larger area of the face in everyday medical practice.
This Phase 1/2 trial tests EscharEx (an investigational treatment) to see if it is safe and works on a single small basal cell skin cancer on the trunk or upper arms. You might qualify if your cancer fits specific size and location rules and you have not had radiation to that spot.
This study tests whether 5-fluorouracil and calcipotriene (medicines used on the skin) can treat certain small, early skin cancers or pre-cancers without surgery. It’s for specific types and locations of lesions and aims to see how well the treatment works and how safe it is.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
Hear when a new Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.